The current price of HUMA is $0.4482 — it has increased by 13.32% since the previous close. Data as of Nov 6, 2026.
HUMA is up 5.78% over the past week, down 5.10% over the past month and down 66.30% over the past year. The price is below its 200-day moving average of $0.7907.
Analysts' average 12-month price target for HUMA is $1.50, which implies 234.67% upside from the current price. Individual estimates range from $1.00 to $2.00.
Of the 6 analysts covering Humacyte, Inc., 1 rates it a strong buy, 3 rate it a buy and 2 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Humacyte, Inc. has a market capitalization of $124.51M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Humacyte, Inc. posted a loss of $0.16 per share against an estimate of -$0.1134, missing expectations by 41.04%. Upcoming reports are listed in the earnings calendar.
Humacyte, Inc. reported revenue of $406K in its most recent quarter, which has increased by 34.88% compared with the same quarter a year earlier. Analysts had expected $1.04M.
Humacyte, Inc. has not paid any dividends over the past year.
In the latest trading session HUMA moved between $0.3999 and $0.4492, a range of 11.00% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Humacyte, Inc. shows a neutral rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Humacyte, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks HUMA has traded between $0.337 and $1.53. The current price is 70.71% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.